Video
Dr. Dummer on NEMO Trial for NRAS-Mutant Melanoma
Author(s):
Reinhard Dummer, MD, professor, Department of Dermatology, University of Zurich Hospital, discusses the results of the phase III NEMO trial, which compared the efficacy of binimetinib with dacarbazine in patients with NRAS-mutant metastatic melanoma.
Reinhard Dummer, MD, professor, Department of Dermatology, University of Zurich Hospital, discusses the results of the phase III NEMO trial, which compared the efficacy of binimetinib with dacarbazine in patients with NRAS-mutant metastatic melanoma.
In the study, patients were randomized to receive the combination of the MEK inhibitor binimetinib and dacarbazine or dacarbazine alone. The combination arm demonstrated a significant improvement in progression-free survival (PFS), with a hazard ratio of 0.62, Dummer explains.
In a separate analysis that examined the efficacy of the combination in patients who were previously treated with an immunotherapy agent, the benefit was higher than in the overall patient population. In these patients, the median progression-free survival was 5.5 months versus 1.6 months with the combination and dacarbazine alone, respectively.
These findings demonstrate binimetinib's potential as an alternative treatment options for patients with NRAS-mutant melanoma.
<<<
